Senti Biosciences Holdings, Inc. - 10-Q Summary (Q3 2024)
Business Context and Reporting Period
Senti Biosciences, Inc. (SNTI) is an early clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. The company focuses on oncology indications, with SENTI-202 (CAR-NK therapy for acute myeloid leukemia) currently in Phase 1 clinical trials. This report covers the quarterly period ended September 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0 | $0.3 million | $0 | $2.6 million |
| Net Loss | $(28.9) million | $(14.9) million | $(52.2) million | $(52.3) million |
| Operating Expenses | $15.2 million | $44.2 million | $44.9 million | $76.6 million |
| Cash and Cash Equivalents | $10.5 million | $35.9 million (Dec 31, 2023) | $10.5 million | $35.9 million (Dec 31, 2023) |
| Accumulated Deficit | $(296.5) million | $(244.3) million (Dec 31, 2023) | $(296.5) million | $(244.3) million (Dec 31, 2023) |
| Net Cash Used in Operating Activities | N/A | N/A | $(27.9) million | $(45.4) million |
Note: All figures are in thousands unless otherwise noted. Revenue consists of contract revenue and grant income. The company generated no revenue in Q3 2024 or YTD 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped to zero in Q3 2024 compared to $0.3 million in Q3 2023, primarily due to the completion of research services under the Spark Therapeutics collaboration and the SBIR grant in the prior year.
- Operating Expense Reduction: Total operating expenses decreased significantly to $15.2 million in Q3 2024 from $44.2 million in Q3 2023. This reduction is largely attributable to the absence of a $25.7 million impairment charge on long-lived assets recorded in Q3 2023 related to the Alameda facility sublease to GeneFab.
- Other Income/Expense Volatility: Net other income (expense) swung from a gain of $7.3 million in Q3 2023 to a loss of $13.7 million in Q3 2024. This was driven by a $17.4 million loss from the change in fair value of the GeneFab Note Receivable (written down to zero) and a $0.4 million loss on the GeneFab Economic Share, partially offset by a $2.4 million gain on the GeneFab Option and $1.7 million in sublease income.
- Liquidity Position: Cash and cash equivalents decreased from $35.9 million at year-end 2023 to $10.5 million as of September 30, 2024, reflecting a net cash burn of $27.9 million over the first nine months of 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance date. Cash on hand ($10.5 million) is deemed insufficient to fund operations beyond this period without additional financing.
- Strategic Focus: The company is streamlining operations to focus resources on the clinical development of SENTI-202 and the SENTI-301A partnership in China with Celest Therapeutics.
- GeneFab Transaction Impact: The company disposed of its non-oncology business and manufacturing assets to GeneFab in August 2023. As of Q3 2024, the fair value of the GeneFab Note Receivable, Economic Share, and Option were all written down to zero due to the low probability of signing the requisite license agreement to trigger these values.
- CIRM Grant: In August 2024, the company secured an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM) for SENTI-202 development. $2.4 million was received by period end, with subsequent milestone payments received in November 2024.
- Nasdaq Compliance: The company regained compliance with the Nasdaq minimum bid price requirement following a 1-for-10 reverse stock split in July 2024. However, as of October 2024, the company received notice of non-compliance with Nasdaq audit committee requirements due to a vacancy, with a cure period ending December 9, 2024.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to insufficient resources for complex transactions, which is currently being remediated.
Key Facts for Investor Verification
- Liquidity Runway: Verify the company's ability to secure additional capital to fund operations beyond the next 12 months, given the substantial doubt on going concern status.
- GeneFab Valuation: Confirm the rationale for writing down the GeneFab Note Receivable, Economic Share, and Option to zero fair value and the likelihood of future recovery or alternative monetization.
- CIRM Grant Milestones: Monitor the achievement of operational milestones required to receive the remaining tranches of the $8.0 million CIRM grant.
- Nasdaq Listing Status: Track the company's progress in regaining compliance with Nasdaq audit committee requirements by the December 9, 2024 deadline.
- Remediation of Material Weakness: Assess the effectiveness of remediation efforts regarding the material weakness in internal controls over financial reporting.
- Reverse Stock Split Impact: Note that all share and per-share data have been retroactively adjusted for the 1-for-10 reverse stock split effective July 17, 2024.